U.S. Professional Acne Medication Market by Acne Type (Inflammatory Acne and Non-inflammatory Acne), by Formulation (Topical Medications and Oral Medications), by Therapeutic Class (Retinoids, Antibiotics, Salicylic Acid, Benzoyl Peroxide, and Others), and by Distribution Channel (Med Spa, Aesthetician, Dermatologist, and Other Professional Channels) – Opportunity Analysis and Industry Forecast, 2024–2030

U.S. Professional Acne Medication Market

Industry:  Consumer Goods | Publish Date: Feb 2024 | No of Pages:  110 | No. Tables:  77 | No. Figures:  42

Market Definition

The U.S. Professional Acne Medication Market was valued at USD 1233.10 million in 2023 and is predicted to reach USD 1623.77 million by 2030, with a CAGR of 4.01% from 2024 to 2030. The professional acne medication market encompasses specialized skincare formulations designed and prescribed by dermatologists and skincare professionals to address acne-related concerns. Its primary objectives include providing targeted and effective solutions for various types of acne, such as inflammatory and non-inflammatory lesions, and preventing acne scarring.

The advantages of professional acne medication lie in their potent and tailored formulations, often incorporating clinically proven ingredients that may be more intensive than over-the-counter alternatives. Widely used in dermatology practices, these medications cater to individuals with severe or persistent acne concerns, offering a higher level of efficacy and control. As the demand for advanced skincare solutions rises, the professional acne medication market continues to play a crucial role in promoting clearer, healthier skin through personalized and medically guided approaches.

Growing Focus on Holistic Skincare Boosts the Market

The U.S. professional acne medication market is experiencing notable growth driven by the adoption of wellness and holistic approaches in respect to achieving flawless skin. There's a discernible shift towards integrating acne management into comprehensive wellness strategies. The emphasis on holistic care acknowledges the interconnectedness of physical, mental, and emotional health, and by offering treatments that consider these broader aspects of wellness, the market has positioned itself to meet the diverse and evolving demands of patients, thereby fuelling its expansion and aligning with the increasingly holistic approach to healthcare in the U.S.

 

Application of Innovative Technologies Fuelling Growth of the Market

Continuous innovations in dermatological technology have been a driving force behind the robust growth of the professional acne medication market in the United States. These advancements encompass the integration of cutting-edge treatments, such as photopneumatic technology, as exemplified by the TheraClear X Acne System. This system is purpose-built for treating mild-to-moderate acne vulgaris. Recently, Legit.Health launched ALADIN (Automatic Lesion and Density Index), an artificial intelligence algorithm that revolutionized the future of acne treatment. ALADIN harnesses the power of computer vision technology to swiftly and accurately assess acne lesions, providing patients with personalized treatment recommendations in a matter of seconds. 

 

The High Treatment Costs of Acne Medicine Limits Market Expansion

In the U.S., the high costs associated with professional acne medication are a significant constraint on market growth. The advanced procedures such as laser therapy and chemical peels, while highly effective, tend to be more costly compared to over-the-counter alternatives, discouraging those with budget constraints. Consequently, individuals deterred by the elevated costs may opt for more economical solutions, thereby limiting the market's growth potential. 

Tailored Treatment Solutions Creates Growth Opportunity for the Market

The prospect of tailoring treatments to meet individual needs, including genetic factors and specific skin types, presents a promising opportunity for improving treatment outcomes and expanding the patient base. Customized treatment solutions can enhance the effectiveness of professional acne medication, making it more appealing to a wider range of patients seeking personalized care. This personalized approach aligns with the increasing demand for individualized healthcare, offering significant growth potential within the professional acne medication industry for the near future.

 

Competitive Landscape

The U.S. professional acne medication industry includes several market players such as Almirall SA, Bausch Health Companies, Inc., GlaxoSmithKline Plc (GSK), Galderma SA, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, STRATA Skin Sciences, Inc., Mayne Pharma Group Limited, and Pfizer, Inc., and others.

U.S. Professional Acne Medication Market Key Segments

By Acne Type    

  • Inflammatory Acne 

  • Non-inflammatory Acne 

By Formulation    

  • Topical Medications

  • Oral Medications 

By Therapeutic Class

  • Retinoids

  • Antibiotics

  • Salicylic Acid

  • Benzoyl Peroxide

  • Others

By Distribution Channel

  • Med Spa

  • Aesthetician

  • Dermatologist

  • Other Professional Channels

REPORT SCOPE AND SEGMENTATION:

Parameters

Details

Market Size in 2023

USD 1233.10 Million

Revenue Forecast in 2030

USD 1623.77 Million

Growth Rate

CAGR of 4.01% from 2024 to 2030

Analysis Period

2023–2030

Base Year Considered

2023

Forecast Period

2024–2030

Market Size Estimation

Million (USD)

Growth Factors

Growing embrace of holistic skincare approach.

Integration of innovative technologies in acne treatment.

Companies Profiled

10

Market Share

Available for 10 companies

Customization Scope

Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs.

Test

1      INTRODUCTION

           1.1      REPORT DESCRIPTION

           1.2      RESEARCH METHODOLOGY

                         1.2.1      SECONDARY RESEARCH

                         1.2.2      DATA ANALYSIS FRAMEWORK

                         1.2.3      MARKET SIZE ESTIMATION

                         1.2.4      FORECASTING

                         1.2.5      PRIMARY RESEARCH AND DATA VALIDATION

2      U.S. PROFESSIONAL ACNE MEDICATION MARKET – EXECUTIVE SUMMARY

           2.1.      MARKET SNAPSHOT, 2023 - 2030, MILLION USD

3      PORTER’S FIVE FORCE MODEL ANALYSIS

           3.1      BARGAINING POWER OF SUPPLIERS

           3.2      BARGAINING POWER OF BUYERS

           3.3      DEGREE OF COMPETITION

           3.4      THREAT OF SUBSTITUTE

           3.5      THREAT OF NEW ENTRANTS

4      MARKET SHARE ANALYSIS

           4.1      MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2023

5      MARKET DYNAMICS

           5.1      GROWTH DRIVERS

                         5.1.1      DRIVER 1

                         5.1.2      DRIVER 2

                         5.1.3      DRIVER 3

                         5.1.4      DRIVER 4

           5.2      CHALLENGES

                         5.2.1      CHALLENGE 1

                         5.2.2      CHALLENGE 2

                         5.2.3      CHALLENGE 3

                         5.2.4      CHALLENGE 4

           5.3      OPPORTUNITIES

                         5.3.1      OPPORTUNITY 1

                         5.3.2      OPPORTUNITY 2

6       U.S. PROFESSIONAL ACNE MEDICATION MARKET BY ACNE TYPE

           6.1      OVERVIEW

           6.2      INFLAMMATORY ACNE MARKET

           6.3      NON-INFLAMMATORY ACNE MARKET

7       U.S. PROFESSIONAL ACNE MEDICATION MARKET BY FORMULATION

           7.1      OVERVIEW

           7.2      TOPICAL MEDICATIONS MARKET

           7.3      ORAL MEDICATIONS MARKET

8       U.S. PROFESSIONAL ACNE MEDICATION MARKET BY THERAPEUTIC CLASS

           8.1      OVERVIEW

           8.2      RETINOIDS MARKET

           8.3      ANTIBIOTICS MARKET

           8.4      SALICYLIC ACID MARKET

           8.5      BENZOYL PEROXIDE MARKET

           8.6      OTHERS MARKET

9       U.S. PROFESSIONAL ACNE MEDICATION MARKET BY DISTRIBUTION CHANNEL

           9.1      OVERVIEW

           9.2      MED SPA MARKET

           9.3      AESTHETICIAN MARKET

           9.4      DERMATOLOGIST MARKET

           9.5      OTHER PROFESSIONAL CHANNELS MARKET

10   COMPANY PROFILES

           10.1   ALMIRALL S.A.

                         10.1.1   COMPANY OVERVIEW

                         10.1.2   COMPANY SNAPSHOT

                         10.1.3   OPERATING BUSINESS SEGMENTS

                         10.1.4   PRODUCT PORTFOLIO

                         10.1.5   BUSINESS PERFORMANCE

                         10.1.6   BUSINESS SEGMENTS

                         10.1.7   GEOGRAPHIC SEGMENTS

                         10.1.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.1.9   PRIMARY MARKET COMPETITORS

           10.2   BAUSCH HEALTH COMPANIES, INC.

                         10.2.1   COMPANY OVERVIEW

                         10.2.2   COMPANY SNAPSHOT

                         10.2.3   OPERATING BUSINESS SEGMENTS

                         10.2.4   PRODUCT PORTFOLIO

                         10.2.5   BUSINESS PERFORMANCE

                         10.2.6   BUSINESS SEGMENTS

                         10.2.7   GEOGRAPHIC SEGMENTS

                         10.2.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.2.9   PRIMARY MARKET COMPETITORS

           10.3   GLAXOSMITHKLINE PLC (GSK)

                         10.3.1   COMPANY OVERVIEW

                         10.3.2   COMPANY SNAPSHOT

                         10.3.3   OPERATING BUSINESS SEGMENTS

                         10.3.4   PRODUCT PORTFOLIO

                         10.3.5   BUSINESS PERFORMANCE

                         10.3.6   BUSINESS SEGMENTS

                         10.3.7   GEOGRAPHIC SEGMENTS

                         10.3.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.3.9   PRIMARY MARKET COMPETITORS

           10.4   GALDERMA S.A.

                         10.4.1   COMPANY OVERVIEW

                         10.4.2   COMPANY SNAPSHOT

                         10.4.3   OPERATING BUSINESS SEGMENTS

                         10.4.4   PRODUCT PORTFOLIO

                         10.4.5   BUSINESS PERFORMANCE

                         10.4.6   BUSINESS SEGMENTS

                         10.4.7   GEOGRAPHIC SEGMENTS

                         10.4.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.4.9   PRIMARY MARKET COMPETITORS

           10.5   SUN PHARMACEUTICAL INDUSTRIES LIMITED

                         10.5.1   COMPANY OVERVIEW

                         10.5.2   COMPANY SNAPSHOT

                         10.5.3   OPERATING BUSINESS SEGMENTS

                         10.5.4   PRODUCT PORTFOLIO

                         10.5.5   BUSINESS PERFORMANCE

                         10.5.6   BUSINESS SEGMENTS

                         10.5.7   GEOGRAPHIC SEGMENTS

                         10.5.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.5.9   PRIMARY MARKET COMPETITORS

           10.6   TEVA PHARMACEUTICAL INDUSTRIES LTD.

                         10.6.1   COMPANY OVERVIEW

                         10.6.2   COMPANY SNAPSHOT

                         10.6.3   OPERATING BUSINESS SEGMENTS

                         10.6.4   PRODUCT PORTFOLIO

                         10.6.5   BUSINESS PERFORMANCE

                         10.6.6   BUSINESS SEGMENTS

                         10.6.7   GEOGRAPHIC SEGMENTS

                         10.6.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.6.9   PRIMARY MARKET COMPETITORS

           10.7   JOHNSON AND JOHNSON

                         10.7.1   COMPANY OVERVIEW

                         10.7.2   COMPANY SNAPSHOT

                         10.7.3   OPERATING BUSINESS SEGMENTS

                         10.7.4   PRODUCT PORTFOLIO

                         10.7.5   BUSINESS PERFORMANCE

                         10.7.6   BUSINESS SEGMENTS

                         10.7.7   GEOGRAPHIC SEGMENTS

                         10.7.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.7.9   PRIMARY MARKET COMPETITORS

           10.8   ELI LILLY AND COMPANY

                         10.8.1   COMPANY OVERVIEW

                         10.8.2   COMPANY SNAPSHOT

                         10.8.3   OPERATING BUSINESS SEGMENTS

                         10.8.4   PRODUCT PORTFOLIO

                         10.8.5   BUSINESS PERFORMANCE

                         10.8.6   BUSINESS SEGMENTS

                         10.8.7   GEOGRAPHIC SEGMENTS

                         10.8.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.8.9   PRIMARY MARKET COMPETITORS

           10.9   MYLAN N.V.

                         10.9.1   COMPANY OVERVIEW

                         10.9.2   COMPANY SNAPSHOT

                         10.9.3   OPERATING BUSINESS SEGMENTS

                         10.9.4   PRODUCT PORTFOLIO

                         10.9.5   BUSINESS PERFORMANCE

                         10.9.6   BUSINESS SEGMENTS

                         10.9.7   GEOGRAPHIC SEGMENTS

                         10.9.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.9.9   PRIMARY MARKET COMPETITORS

           10.10   DAIICHI SANKYO COMPANY, LTD

                         10.10.1   COMPANY OVERVIEW

                         10.10.2   COMPANY SNAPSHOT

                         10.10.3   OPERATING BUSINESS SEGMENTS

                         10.10.4   PRODUCT PORTFOLIO

                         10.10.5   BUSINESS PERFORMANCE

                         10.10.6   BUSINESS SEGMENTS

                         10.10.7   GEOGRAPHIC SEGMENTS

                         10.10.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.10.9   PRIMARY MARKET COMPETITORS

LIST OF TABLES

TABLE 1. U.S. PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

TABLE 2. INFLAMMATORY ACNE , MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 3. NON-INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 4. U.S. PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

TABLE 5. TOPICAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 6. ORAL MEDICATIONS , MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 7. U.S. PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

TABLE 8. RETINOIDS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 9. ANTIBIOTICS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 10. SALICYLIC ACID, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 11. BENZOYL PEROXIDE, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 12. OTHERS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 13. U.S. PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

TABLE 14. MED SPA, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 15. AESTHETICIAN, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 16. DERMATOLOGIST, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 17. OTHER PROFESSIONAL CHANNELS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 18. ALMIRALL SA: COMPANY SNAPSHOT

TABLE 19. ALMIRALL SA: OPERATING BUSINESS SEGMENTS

TABLE 20. ALMIRALL SA: PRODUCT PORTFOLIO

TABLE 21. ALMIRALL SA: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 22. ALMIRALL SA: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 23. ALMIRALL SA: KEY STRATERGY

TABLE 24. BAUSCH HEALTH COMPANIES, INC.: COMPANY SNAPSHOT

TABLE 25. BAUSCH HEALTH COMPANIES, INC.: OPERATING BUSINESS SEGMENTS

TABLE 26. BAUSCH HEALTH COMPANIES, INC.: PRODUCT PORTFOLIO

TABLE 27. BAUSCH HEALTH COMPANIES, INC.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 28. BAUSCH HEALTH COMPANIES, INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 29. BAUSCH HEALTH COMPANIES, INC.: KEY STRATERGY

TABLE 30. GLAXOSMITHKLINE PLC (GSK): COMPANY SNAPSHOT

TABLE 31. GLAXOSMITHKLINE PLC (GSK): OPERATING BUSINESS SEGMENTS

TABLE 32. GLAXOSMITHKLINE PLC (GSK): PRODUCT PORTFOLIO

TABLE 33. GLAXOSMITHKLINE PLC (GSK): SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 34. GLAXOSMITHKLINE PLC (GSK): SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 35. GLAXOSMITHKLINE PLC (GSK): KEY STRATERGY

TABLE 36. GALDERMA S.A.: COMPANY SNAPSHOT

TABLE 37. GALDERMA S.A.: OPERATING BUSINESS SEGMENTS

TABLE 38. GALDERMA S.A.: PRODUCT PORTFOLIO

TABLE 39. GALDERMA S.A.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 40. GALDERMA S.A.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 41. GALDERMA S.A.: KEY STRATERGY

TABLE 42. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT

TABLE 43. SUN PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING BUSINESS SEGMENTS

TABLE 44. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO

TABLE 45. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 46. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 47. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGY

TABLE 48. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT

TABLE 49. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING BUSINESS SEGMENTS

TABLE 50. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO

TABLE 51. TEVA PHARMACEUTICAL INDUSTRIES LTD.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 52. TEVA PHARMACEUTICAL INDUSTRIES LTD.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 53. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGY

TABLE 54. JOHNSON AND JOHNSON: COMPANY SNAPSHOT

TABLE 55. JOHNSON AND JOHNSON: OPERATING BUSINESS SEGMENTS

TABLE 56. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO

TABLE 57. JOHNSON AND JOHNSON: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 58. JOHNSON AND JOHNSON: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 59. JOHNSON AND JOHNSON: KEY STRATERGY

TABLE 60. STRATA SKIN SCIENCES, INC.: COMPANY SNAPSHOT

TABLE 61. STRATA SKIN SCIENCES, INC.: OPERATING BUSINESS SEGMENTS

TABLE 62. STRATA SKIN SCIENCES, INC.: PRODUCT PORTFOLIO

TABLE 63. STRATA SKIN SCIENCES, INC.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 64. STRATA SKIN SCIENCES, INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 65. STRATA SKIN SCIENCES, INC.: KEY STRATERGY

TABLE 66. MAYNE PHARMA GROUP LIMITED: COMPANY SNAPSHOT

TABLE 67. MAYNE PHARMA GROUP LIMITED: OPERATING BUSINESS SEGMENTS

TABLE 68. MAYNE PHARMA GROUP LIMITED: PRODUCT PORTFOLIO

TABLE 69. MAYNE PHARMA GROUP LIMITED: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 70. MAYNE PHARMA GROUP LIMITED: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 71. MAYNE PHARMA GROUP LIMITED: KEY STRATERGY

TABLE 72. PFIZER, INC.: COMPANY SNAPSHOT

TABLE 73. PFIZER, INC.: OPERATING BUSINESS SEGMENTS

TABLE 74. PFIZER, INC.: PRODUCT PORTFOLIO

TABLE 75. PFIZER, INC.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 76. PFIZER, INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 77. PFIZER, INC.: KEY STRATERGY

LIST OF FIGURES

FIGURE 1. BARGAINING POWER OF SUPPLIERS

FIGURE 2. BARGAINING POWER OF BUYERS

FIGURE 3. DEGREE OF COMPETITION

FIGURE 4. THREAT OF SUBSTITUTE

FIGURE 5. THREAT OF NEW ENTRANTS

FIGURE 6. U.S. PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

FIGURE 7. INFLAMMATORY ACNE , MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 8. NON-INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 9. U.S. PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

FIGURE 10. TOPICAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 11. ORAL MEDICATIONS , MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 12. U.S. PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

FIGURE 13. RETINOIDS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 14. ANTIBIOTICS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 15. SALICYLIC ACID, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 16. BENZOYL PEROXIDE, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 17. OTHERS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 18. U.S. PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

FIGURE 19. MED SPA, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 20. AESTHETICIAN, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 21. DERMATOLOGIST, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 22. OTHER PROFESSIONAL CHANNELS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 23. ALMIRALL SA: NET SALES, (2021-2023)

FIGURE 24. ALMIRALL SA: PRIMARY MARKET COMPETITORS

FIGURE 25. BAUSCH HEALTH COMPANIES, INC.: NET SALES, (2021-2023)

FIGURE 26. BAUSCH HEALTH COMPANIES, INC.: PRIMARY MARKET COMPETITORS

FIGURE 27. GLAXOSMITHKLINE PLC (GSK): NET SALES, (2021-2023)

FIGURE 28. GLAXOSMITHKLINE PLC (GSK): PRIMARY MARKET COMPETITORS

FIGURE 29. GALDERMA S.A.: NET SALES, (2021-2023)

FIGURE 30. GALDERMA S.A.: PRIMARY MARKET COMPETITORS

FIGURE 31. SUN PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES, (2021-2023)

FIGURE 32. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRIMARY MARKET COMPETITORS

FIGURE 33. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, (2021-2023)

FIGURE 34. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRIMARY MARKET COMPETITORS

FIGURE 35. JOHNSON AND JOHNSON: NET SALES, (2021-2023)

FIGURE 36. JOHNSON AND JOHNSON: PRIMARY MARKET COMPETITORS

FIGURE 37. STRATA SKIN SCIENCES, INC.: NET SALES, (2021-2023)

FIGURE 38. STRATA SKIN SCIENCES, INC.: PRIMARY MARKET COMPETITORS

FIGURE 39. MAYNE PHARMA GROUP LIMITED: NET SALES, (2021-2023)

FIGURE 40. MAYNE PHARMA GROUP LIMITED: PRIMARY MARKET COMPETITORS

FIGURE 41. PFIZER, INC.: NET SALES, (2021-2023)

FIGURE 42. PFIZER, INC.: PRIMARY MARKET COMPETITORS

KEY PLAYERS

  • Almirall SA

  • Bausch Health Companies, Inc.

  • GlaxoSmithKline Plc (GSK)

  • Galderma SA

  • Sun Pharmaceutical Industries Limited

  • Teva Pharmaceutical Industries Ltd.

  • Johnson & Johnson

  • STRATA Skin Sciences, Inc.

  • Mayne Pharma Group Limited

  • Pfizer, Inc.


Frequently Asked Questions
What will be the worth of the U.S. professional acne medication market by the end of 2030?

According to the report published by Next Move Consulting, the U.S. professional acne medication market business is expected to hit at USD 1623.77 million by 2030.

What are the leading companies in the U.S. professional acne medication market?

The North American professional acne medication industry includes several market players such as Almirall SA, Bausch Health Companies, Inc., GlaxoSmithKline Plc (GSK), Galderma SA, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, STRATA Skin Sciences, Inc., Mayne Pharma Group Limited, and Pfizer, Inc., and others.

What are the market segmentations and scope of the study for the U.S. professional acne medication industry?

The U.S. Professional acne medication market share is segmented based on acne type, formulation, therapeutic class, distribution channel, and geography.

What are the factors that are driving the growth of the professional acne medication market in the U.S.?

The factors driving the growth of the Professional acne medication market in the U.S. include the growing embrace of holistic wellness and the integration of innovative technologies in acne treatment.

What is restraining the growth of the U.S. professional acne medication market?

The high treatment costs of professional acne medicine limit market expansion in the U.S.